WHITE GLOVE APPOINTS JEFF BAJOREK AS NEW CHIEF SALES OFFICER
Company aims to fortify its executive leadership team post-merger with TouchFuse
Bajorek joins White Glove with a wealth of experience, having spent the past nine years as an independent sales consultant, trainer, and speaker, primarily assisting professional service firms. Prior to his consultancy work, he excelled as a top performer in the medical device industry, underscoring his commitment to results-driven performance.
"We are thrilled to welcome Jeff to our team as
This announcement comes on the heels of White Glove's strategic merger with TouchFuse, which includes the LeadJig, Prospectix and Acquire Direct businesses. The combined entity now stands as the largest, full-service, omni-channel marketing services company dedicated exclusively to financial professionals. As part of its post-merger strategy, White Glove aims to fortify its executive leadership team to capitalize on emerging opportunities and drive sustainable growth.
Bajorek expressed his enthusiasm for joining White Glove, stating, "I am inspired by the exceptional talent within this team and their commitment to continuous learning and development. With the recent merger with TouchFuse and our expanded portfolio of services, we are poised to make a significant impact on the financial futures of hundreds of thousands of individuals."
The combined company remains committed to equipping financial advisors with the tools and resources they need to succeed in today's competitive landscape while helping them empower consumers on their path toward financial independence.
About White Glove
Based in
About TouchFuse
Founded in 1986 and based in
Media Inquires
White Glove
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/white-glove-appoints-jeff-bajorek-as-new-chief-sales-officer-302089513.html
SOURCE White Glove
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citadel unwinds 80% of Aschenbrenner’s portfolio risk - report
- Benz Announces A$150m Placement to Accelerate Delivery of Glenburgh Maiden Resource
- Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share